Cited by 32Nanoparticle-Based Drug DeliveryAdvanced Drug Delivery SystemsNanoplatforms for cancer theranostics

Redox-Responsive Amphipathic Dextran Nanomicelles for Solid Tumor Therapy

Song, Yanyan, Lou, Bo, Cheng, Jian, Zhao, Peng, Lin, Chao, Wen, Xuejun·2016·Journal of Biomedical Nanotechnology

Abstract

A disulfide bond containing deoxycholic acid-grafted dextran (Dex-SSDCA) was successfully prepared for drug delivery. The Dex-SSDCA polymers can self-assemble into nanomicelles at concentrations below 56 g/mL and encapsulate doxorubicin (DOX) effectively. When exposed to 10 mM Dithiothreitol (DTT), the nanomicelles disassembled rapidly and released DOX immediately. The DOX-loaded Dex-SSDCA nanomicelles were able to reverse the drug resistance of MCF-7/Adr cells and inhibit their growth in vitro. Moreover, DOX-loaded Dex-SSDCA nanomicelles could significantly suppress the growth of subcutaneous SKOV-3 ovarian cancer in vivo, exerting stronger efficiency on inhibiting tumor angiogenesis and proliferation while aggravating apoptosis of tumor cells, in comparison with the negative control and free DOX. The in vivo toxicity evaluation demonstrated that the Dex-SSDCA micelles reduced DOX-induced side effects. This redoxresponsive amphipathic dextran is able to enhance the antitumor efficiency and reduce the toxicity of doxorubicin, thus has a potential as a drug carrier for cancer therapy.

Integrity signals

Registry

Crossref · 10.1166/jbn.2016.2314

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The polymer was prone to self-assemble and form nanomicelles at concentrations less than 56 g/mL and could efficiently encapsulate DOX.

    “The polymer was prone to self-assemble and form nanomicelles at concentrations less than 56 g/mL and could efficiently encapsulate DOX.”

    From Recent Advances in Nanomicelles Delivery Systems. (2020) · cites this paper as [220]

  • Alternative nanocarrier for drug delivery was fabricated with deoxycholic acid-grafted dextran (Dex-SSDCA) containing a disulfide bond.

    “Alternative nanocarrier for drug delivery was fabricated with deoxycholic acid-grafted dextran (Dex-SSDCA) containing a disulfide bond [220].”

    From Recent Advances in Nanomicelles Delivery Systems. (2020) · cites this paper as [220]

  • Rapid disassembly was observed upon exposure to 10 mM Dithiothreitol (DTT) which led to the immediate release of DOX.

    “Rapid disassembly was observed upon exposure to 10 mM Dithiothreitol (DTT) which led to the immediate release of DOX.”

    From Recent Advances in Nanomicelles Delivery Systems. (2020) · cites this paper as [220]

  • This drug delivery system demonstrated in vivo significant suppression of subcutaneous SKOV-3 ovarian cancer cells with notable inhibition of tumor angiogenesis and proliferation and enhanced apoptosis when compared with free DOX and negative control.

    “This drug delivery system demonstrated in vivo significant suppression of subcutaneous SKOV-3 ovarian cancer cells with notable inhibition of tumor angiogenesis and proliferation and enhanced apoptosis when compared with free DOX and negative control.”

    From Recent Advances in Nanomicelles Delivery Systems. (2020) · cites this paper as [220]

  • In vitro studies showed that DOX-loaded Dex-SSDCA nanomicelles considerably diminished drug resistance of MCF-7/Adr cells and inhibited their growth.

    “In vitro studies showed that DOX-loaded Dex-SSDCA nanomicelles considerably diminished drug resistance of MCF-7/Adr cells and inhibited their growth.”

    From Recent Advances in Nanomicelles Delivery Systems. (2020) · cites this paper as [220]

Cited by

Sorted by citations

Authors
Song, Y., Lou, B., Cheng, J., Zhao, P., Lin, C., & Wen, X.
Venue
Journal of Biomedical Nanotechnology
Published
2016-12-01
Volume
12
Issue
12
Pages
2083-2096
ISSN
1550-7033 (ISSN-L)
OpenAlex
W2547780699
Cited by
32
References
0
Citations by year
2026: 3 · 2023: 3 · 2022: 3 · 2021: 3 · 2020: 2 · 2019: 4 · 2018: 3 · 2017: 11
FWCI
2.45
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Biomedical Nanotechnology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
Keywords
disulfide bonds, doxorubicin delivery, drug resistance reversal, MCF-7/ADR cells, ovarian cancer, tumor angiogenesis, apoptosis, drug toxicity reduction, self-assembly
MeSH terms
Animals, Antineoplastic Agents, Cell Survival, Dextrans, Dithiothreitol, Doxorubicin, Drug Carriers, Humans, Male, Mice, Nude, Micelles, Oxidation-Reduction, Apoptosis, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Nanoparticles, MCF-7 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review